This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued
The U.S. Food and Drug Administration (FDA) has approved the first immunotherapy regimen shown to extend survival in a subset of ovarian cancer patients. The FDA authorized Keytruda (pembrolizumab), made by Merck, in combination with chemotherapy, for PD-L1–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. Keytruda plus weekly Taxol (paclitaxel), with or without … Continued
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued
In 2025, Ovarian Cancer Research Alliance (OCRA) invested more than $10.8 million toward scientific research—part of our $14.5 million commitment to strengthen the community through research, patient support, education and advocacy. This year’s investment represents OCRA’s broadest scope to date, encompassing not only our renowned grant programs but also global collaborations leveraging artificial intelligence (AI) … Continued
KVIA-TV ABC-7 News El Paso recently spotlighted the groundbreaking work of OCRA-funded researcher Daniel Heller, PhD of Memorial Sloan Kettering Cancer Center, whose research lab is working to develop a liquid biopsy that uses nanotechnology and artificial intelligence (AI) to detect ovarian cancer earlier. We’re developing a liquid biopsy that uses nano sensors and AI … Continued
Scientists have identified sixteen potential therapeutic targets in low-grade serous ovarian cancer by studying proteins at the molecular level, with results published on August 11, 2025, in the journal Cancer Cell. The research was led by Ernst Lengyel, MD, PhD of University of Chicago, along with Matthias Mann, PhD, of the Max Planck Institute of … Continued
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC) who have a KRAS mutation. The approval is based on the results of the Phase 2 RAMP 201 clinical … Continued
Research Breakthrough: A team of researchers at The University of Texas Health Science Center developed a pioneering AI tool to better predict treatment response, a step toward earlier personalized treatment plans. The researchers created a new artificial intelligence tool that uses images from diagnostic laparoscopy, minimally invasive camera-made images taken inside the abdomen, to predict how patients … Continued
Get email updates about research news, action alerts, and ways to join the fight.
